This company has been marked as potentially delisted and may not be actively trading. Melinta Therapeutics (MLNT) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Melinta Therapeutics Announces IDWeek 2024 Presentations Focused on Melinta’s Portfolio of Commercial and Investigational Stage ProductsOctober 17, 2024 | finance.yahoo.comMelinta Therapeutics Announces the Appointment of Sunitha Lakshminarayanan, as Chief Technology OfficerSeptember 5, 2024 | finance.yahoo.comSWTX SpringWorks Therapeutics, Inc.April 23, 2024 | seekingalpha.comFDA Requests Additional Data for Venatorx and Melinta's Antibiotic CombinationFebruary 28, 2024 | msn.comPromising Phase 3 Results for Cefepime-Taniborbactam in Treating Complicated UTIsFebruary 27, 2024 | msn.comVenatorx and Melinta Provide Update on Status of U.S. New Drug Application for Cefepime-TaniborbactamFebruary 23, 2024 | finance.yahoo.comCidara, Melinta announce publication of Rezzayo data in medical journalDecember 5, 2023 | msn.comMelinta Therapeutics and Venatorx Pharmaceuticals Announce Licensing Agreement to Commercialize Cefepime-Taniborbactam in the U.S.November 9, 2023 | finance.yahoo.comMelinta Therapeutics Announces Presentations of New Data on Infectious Disease Portfolio at IDWeek 2023October 11, 2023 | finance.yahoo.comMelinta Therapeutics Announces Expanded Reimbursement and Access for REZZAYO™ (rezafungin for injection)October 2, 2023 | uk.finance.yahoo.comMelinta Therapeutics, Inc.September 26, 2023 | thestreet.comMelinta Therapeutics and Xediton Pharmaceuticals Announce Licensing Agreement to Commercialize Anti-Infective Products in CanadaMay 15, 2023 | finance.yahoo.comCidara Therapeutics Sheds Skin, Shifts To ImmunotherapyMarch 1, 2023 | seekingalpha.comBiVictriX Therapeutics reports "really exciting" BCX001 dataFebruary 24, 2023 | finance.yahoo.comOptimizeRx and Melinta Therapeutics Present Third Annual Innovate4Outcomes(R) Healthcare Design Thinking-Inspired EventOctober 20, 2022 | technews.tmcnet.comMelinta Therapeutics and Cidara Therapeutics Announce Licensing Agreement to Commercialize Rezafungin in the U.S.July 27, 2022 | finance.yahoo.comMelinta Therapeutics Announces Appointment of Doug Girgenti as Vice President of Drug DevelopmentOctober 25, 2021 | finance.yahoo.comMelinta Therapeutics Announces Two Key Milestones Expanding Reimbursement and Access for KIMYRSA™ (oritavancin)September 20, 2021 | apnews.com Get Melinta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLNT and its competitors with MarketBeat's FREE daily newsletter. Email Address MLNT Media Mentions By Week MLNT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MLNT News Sentiment▼0.000.86▲Average Medical News Sentiment MLNT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MLNT Articles This Week▼00▲MLNT Articles Average Week Get Melinta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLNT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies LLY News Today JNJ News Today ABBV News Today MRK News Today PFE News Today BMY News Today ZTS News Today RPRX News Today CORT News Today JAZZ News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MLNT) was last updated on 4/28/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | Sponsored‘Wheels Are Falling Off’ the U.S. Stock MarketThe last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredIt’s absolute chaos in Silicon Valley right now…If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Melinta Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Melinta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MLNT Stock Free MLNT Stock Alerts